{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n2.5 \u03bcM 2-ME, 5 \u03bcM 4-HPR, 1 \u03bcg/ml TOC, 2.5 \u03bcM 2-ME and 1 \u03bcg/ml TOC (2T), 5 \u03bcM 4-HPR and 2.5 \u03bcM 2-ME (4T), 5 \u03bcM 4-HPR and 2.5 \u03bcM 2-ME (2+4), or 5 \u03bcM 4-HPR, 2.5 \u03bcM 2-ME, and 1 \u03bcg/ml TOC (Triple) (initial agent concentrations same for single and combinations).\nTOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+PLGA blank implant, 5) 2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+4-HPR releasing PLGA implant, 6) 2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+TOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+blank PLGA implant, 7) TOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+4-HPR releasing PLGA implant, 8) 2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+TOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+4-HPR releasing PLGA implant."}
{"final_json": [{"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "2.5", "unit": "\u03bcM"}, {"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "5", "unit": "\u03bcM"}, {"molecule_name": "TOC", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/ml"}, {"molecule_name": "2-ME and TOC (2T)", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "4-HPR and 2-ME (4T)", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "4-HPR and 2-ME (2+4)", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "5 \u03bcM 4-HPR, 2.5 \u03bcM 2-ME, and 1 \u03bcg/ml TOC (Triple)", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "TOC", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.3", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "TOC", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.3", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "TOC and 2-ME and 4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nIn vitro release can be determined at 37\u00b0 C. under perfect sink conditions using PBS+0.084% Tween 80, which provides the same fenretinide solubility (21 \u03bcg/mL) as found in bovine serum.\nThe drug release could also be strongly increased by numerous additives (for example \u03b2-cyclodextrin, Pluronic F127, or PEG8000) to affect the drug solubility and/or pore formation of the polymer throughout the release period.\nRelease kinetics in vitro can be performed in PBS+0.02% Tween 80 (PBST) at 37\u00b0 C. under perfect sink conditions with HPLC detection.\nIn vitro release can be conducted at 37\u00b0 C. in PBST as for 2-ME, except analysis can be by SEC and ELISA."}
{"final_json": [{"molecule_name": "fenretinide", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "21", "unit": "\u03bcg/mL"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* 5\u00d710<sup>5 </sup>JSCC1 cells (tumorsphere-formation competent unlike JSCC2 and JSCC3 cells) were plated in complete medium with either vehicle control (0.01% DMSO) or 5 \u03bcM 4-HPR in Corning Ultra-Low attachment tissue culture flasks (Sigma-Aldrich, St. Louis, Mo.)\n* Twenty four hour sera-deprived cells were treated for an additional 24 hours in sera free media with the following: ... 4) 1 \u03bcg/ml tocilizumab (TOC, \u02dc2.55 \u03bcM) \n* Sera-free conditioned media for IL-6, VEGF, TGF-\u03b1 and EGF were analyzed by ELISAs (R&amp;D Systems, Minneapolis, Minn.), with data expressed as pg/10<sup>6 </sup>cells."}
{"final_json": [{"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "5", "unit": "\u03bcM"}, {"molecule_name": "tocilizumab", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "2.55", "unit": "\u03bcM"}, {"molecule_name": "IL-6", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": "pg/10^6 cells"}, {"molecule_name": "VEGF", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": "pg/10^6 cells"}, {"molecule_name": "TGF-\u03b1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": "pg/10^6 cells"}, {"molecule_name": "EGF", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": "pg/10^6 cells"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+blank PLGA implant, \n2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+4-HPR releasing PLGA implant, \n2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.)+TOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+blank PLGA implant, \nTOC q.d. (0.3 \u03bcg/100 \u03bcl PBS)+PLGA blank implant, \nTOC q.d. (0.3\u03bcg/100 \u03bcl PBS)+4-HPR releasing PLGA implant, \n2-ME (1 \u03bcg/100 \u03bcl PBS, b.i.d.) +TOC q.d. (0.3\u03bcg/100 \u03bcl PBS)+4-HPR releasing PLGA implant."}
{"final_json": [{"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "TOC", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.3", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "TOC", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.3", "unit": "\u03bcg/100 \u03bcl PBS"}, {"molecule_name": "2-ME", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "\u03bcg/100 \u03bcl PBS"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* 4-HPR implants released between 300-370 \u03bcg drug and achieved tissue levels of 331+/\u2212134 \u03bcM.\n* 4-HPR sera levels were below LLOQ (<50 ng/ml) in all mice that received PLGA implants.\n* IL-6 levels detected (range \u02dc100-1,600 pg/10<sup>6 </sup>cells) were comparable to IL-6 release from other human cancer cells (ovarian 100-200 pg/10<sup>6 </sup>cells, prostate 850-1250 pg/10<sup>6 </sup>cells) \n* VEGF release (range \u02dc1,000-3,000 pg/10<sup>6 </sup>cells) also compared favorably to previous OSCC cell data (1,500 pg/10<sup>6 </sup>cells)"}
{"final_json": [{"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "300-370", "unit": "\u03bcg"}, {"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "331+/\u2212134", "unit": "\u03bcM"}, {"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "<50", "unit": "ng/ml"}, {"molecule_name": "IL-6", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100-1,600", "unit": "pg/10^6 cells"}, {"molecule_name": "IL-6", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100-200", "unit": "pg/10^6 cells"}, {"molecule_name": "IL-6", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "850-1250", "unit": "pg/10^6 cells"}, {"molecule_name": "VEGF", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1,000-3,000", "unit": "pg/10^6 cells"}, {"molecule_name": "VEGF", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1,500", "unit": "pg/10^6 cells"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* Despite achieving tumor 4-HPR levels that were appreciably greater than apoptosis-inducing 10 \u03bcM [21], 4-HPR implants only significantly inhibited tumor growth when used with other agents.\n* Although two established apoptosis-inducing drugs (2-ME and 4-HPR) were employed, low levels of cleaved caspase 3 were detected in all groups (FIGS. 6. and 6C), and 4-HPR was used at levels greater than apoptosis-inducing 10 \u03bcM. \n* Additionally, tocilizumab (100 \u03bcg i.p.) significantly reduced HNSCC tumor initiation in scid mice; \n* In contrast, the data showed appreciably lower local tocilizumab doses (0.3 \u03bcg q.d.) significantly inhibited OSCC tumor growth."}
{"final_json": [{"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "\u03bcM"}, {"molecule_name": "4-HPR", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "\u03bcM"}, {"molecule_name": "tocilizumab", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "\u03bcg"}, {"molecule_name": "tocilizumab", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.3", "unit": "\u03bcg"}]}
